文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺放疗与转移性前列腺癌生存:按疾病负荷分层

Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden.
PubMed 文献 · Radiother Oncol · 2025-09-21

基于美国国家癌症数据库(2004—2020)48,121例新发转移性前列腺癌患者,比较激素治疗联合或不联合前列腺放疗的总生存。倾向评分匹配后,放疗与总生存改善相关(HR 0.62;95%CI 0.58-0.66;p<0.001),获益主要见于M1a和M1b,M1c未见显著获益。

要点

  • 转移性前列腺癌接受激素治疗联合前列腺放疗与总生存改善相关。
  • 获益随转移亚分期不同:M1a获益最大,M1b亦有获益,M1c无显著获益。
  • 分子影像时代需进一步优化前列腺放疗的患者选择。

核心结论

  • 在这项观察性研究中,激素治疗联合前列腺放疗与转移性前列腺癌患者总生存改善相关。
  • 放疗与总生存的关联因转移亚分期而异,M1a获益更大,M1c未见明显获益。

研究设计与样本

  • 基于美国国家癌症数据库(2004—2020)的观察性研究,纳入48,121例新发转移性前列腺癌患者。
  • 42,437例(88.2%)仅接受激素治疗,5,684例(11.8%)接受激素治疗联合前列腺放疗。
  • 采用Kaplan-Meier曲线和多变量比例风险回归模型,在倾向评分匹配样本中比较M1a、M1b、M1c疾病的总生存。

主要发现

  • 倾向评分匹配校正后,放疗与总生存改善相关(HR 0.62;95%CI 0.58-0.66;p<0.001)。
  • M1a疾病患者死亡风险降低(HR 0.48;95%CI 0.39-0.58;p<0.001)。
  • M1b疾病患者死亡风险降低(HR 0.60;95%CI 0.56-0.65;p<0.001)。
  • M1c疾病未见显著总生存获益(HR 0.91;95%CI 0.74-1.13;p<0.001)。

临床怎么用

  • 对低疾病负荷的转移性前列腺癌患者,可考虑在激素治疗基础上联合前列腺放疗。
  • 对M1c疾病患者,前列腺放疗的总生存获益不明确,决策需个体化。

局限性

  • 本研究为观察性研究,存在选择偏倚等混杂因素的可能。
  • 分子影像时代需进一步细化患者选择以优化放疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate radiotherapy (RT) is increasingly used in the treatment of hormone-sensitive metastatic prostate cancer (PCa) based on evidence of benefit in subsets with low disease volume. However, survival outcomes of patients with metastatic PCa receiving prostate RT across contemporary distributions of stage are less well understood. METHODS: Within the National Cancer Database (2004-2020), we identified individuals with de-novo metastatic PCa treated with hormonal therapy (HT) with or without prostate RT. Kaplan-Meier curves and multivariable proportional hazard regression models were used to compare overall survival (OS) across nodal (M1a), bone (M1b), and visceral (M1c) disease, using propensity score matched (PSM) samples. RESULTS: We identified 48,121 eligible patients, including 42,437 (88.2 %) patients receiving only HT and 5,684 (11.8 %) patients receiving HT + RT. In PSM-adjusted hazard regression models, RT was associated with improved OS (HR: 0.62; 95 % CI: 0.58-0.66; p < 0.001). The association differed by metastatic substage; the risk of death was reduced in patients with M1a (HR: 0.48; 95 % CI: 0.39-0.58; p < 0.001) and M1b disease (HR: 0.60; 95 % CI: 0.56-0.65; p < 0.001). No significant OS benefit was observed in M1c disease (HR: 0.91; 95 % CI: 0.74-1.13; p < 0.001). CONCLUSION: Prostate RT with HT was associated with improved survival in this observational study of patients with metastatic PCa. However, these associations differed by metastatic substage, with greater benefit in M1a, and no apparent benefit in M1c disease.In the era of molecular imaging, further refinement of patient selection for prostate RT may optimize treatment benefit.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Palencia PS, Smani S, Zhao X, et al. Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden. Radiother Oncol. 2025. PMID: 40987387. doi:10.1016/j.radonc.2025.111158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。